Influenzavirus A Infections – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23004IDB-L5

Select Item

Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions.

Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza A virus are called hemagglutinin (H) and neuraminidase (N). Different virus subtypes have differences in their surface proteins.

The Influenzavirus A Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenzavirus A Infections and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Influenzavirus A Infections
Key Targets
· Hemagglutinin HA; Hemagglutinin; Neuraminidase; Influenza M2 Proton Channel; Influenza A Virus Nucleoprotein ; Polymerase Basic Protein 2; Neuraminidase A; Polymerase Acidic Protein; Hemagglutinin H7HA; and Hemagglutinin 1
Key Mechanisms of Action
· Hemagglutinin Inhibitor; Neuraminidase Inhibitor; Influenza M2 Proton Channel Blocker; Polymerase Basic Protein 2 Inhibitor; Polymerase Acidic Protein Inhibitor; Influenza A Virus Nucleoprotein Inhibitor; Hemagglutinin HA Inhibitor; Hemagglutinin 5 Inhibitor; Hemagglutinin 1 Inhibitor; and High Mobility Group Protein B1 Inhibitor
Key Routes of Administration
· Intramuscular; Oral; Nasal; Inhalational; Parenteral; Intravenous; Subcutaneous; Intradermal; Transdermal; and Topical
Key Molecule Types
· Small Molecule; Subunit Vaccine; Inactivated Vaccine; mRNA Vaccine; Monoclonal Antibody; Live Attenuated Vaccine; Vaccine; Recombinant Vector Vaccine; Synthetic Peptide; and DNA Vaccine
Major Companies
· The National Institute of Allergy and Infectious Diseases; Moderna Inc; Sanofi; Butantan Institute; Cidara Therapeutics Inc; Cocrystal Pharma Inc; Johnson & Johnson; GSK plc; FluGen Inc; and Inovio Pharmaceuticals Inc

Scope

  • Therapeutics in Development: Covering 240 molecules, with 180 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Influenzavirus A Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Influenzavirus A Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Influenzavirus A Infections treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Abhelix LLC
AbVacc Inc
Abzyme Therapeutics LLC
Acticule Life Sciences Ltd
Adaptive Biotechnologies Corp
Adimmune Corp
AIM ImmunoTech Inc
Alla Chem LLC
Allergy Therapeutics Plc
Amniotics AB
Andikang (Wuxi) Biotechnology Co Ltd
Ansun Biopharma Inc
Aphios Corp
Arizona State University
AusBio Ltd
AVM Biotechnology LLC
Baylor Scott & White Research Institute
Beijing Tiantan Biological Products Co Ltd
BioCryst Pharmaceuticals Inc
BioNTech SE
Biophytis SA
BioTherapeutics Inc
Blue Water Biotech Inc
BlueWillow Biologics Inc
Brandenburg Antiinfektiva GmbH
Brillian Pharma Inc.
BunyaVax BV
Butantan Institute
CEL-SCI Corp
Celdara Medical LLC
Celestial Therapeutics Inc
Changchun Institute of Biological Products Co Ltd
Chicago Biosolutions Inc
Chinese Academy of Sciences
CHO Pharma Inc
Chongqing Zhifei Biological Products Co Ltd
Christian-Albrechts-University of Kiel
Cidara Therapeutics Inc
Cilian AG
Cisen Pharmaceutical Co Ltd
Cocrystal Pharma Inc
Codagenix Inc
Collaborations Pharmaceuticals Inc
ContraFect Corp
Creative Biotherapeutics LLC
CSL Ltd
Curevac NV
CytoAgents Inc
Dalian Ya Li-feng Biological Pharmaceutical Co Ltd
Dnarx LLC
Drexel University
Dultech Advanced Sciences
Dynamic Entropy Technology LLC
e-Therapeutics Plc
Emergent BioSolutions Inc
Emergex Vaccines Holding Ltd
Emory University
ENA Respiratory Pty Ltd
EnGen Bio Inc
EpiVax Inc
Evoq Nano Inc
Evrys Bio
ExpreS2ion Biotech Holding AB
FluGen Inc
Fox Chase Chemical Diversity Center Inc
FUJIFILM Toyama Chemical Co Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
Gamma Vaccines Pty Ltd
Georgia State University
German Center for Infection Research
Global BioLife Inc Ltd
Greffex Inc
GSK plc
Guangdong Raynovent Biotech Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Harvard University
HEC Pharma Co Ltd
Helix Biogen Institute
Hualan Biological Bacterin Co Ltd
IDBiologics Inc
ILiAD Biotechnologies LLC
Ilyang Pharmaceutical Co Ltd
ImmunityBio Inc
Imutex Ltd
Inovio Pharmaceuticals Inc
InterK Peptide Therapeutics Ltd
InvVax Inc
iQur Ltd
Jagiellonian University
Jiangsu Ab&b Bio-tech Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Kangrun Biological Technology Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Joincare Pharmaceutical Group Industry Co Ltd
Lab11 Therapeutics LLC
Lee's Pharmaceutical Holdings Ltd
Leyden Laboratories BV
Liaoning Cheng Da Biotechnology Co Ltd
Longhorn Vaccines and Diagnostics LLC
Massachusetts Institute of Technology
Medigen Inc
Meletios Therapeutics SAS
Microbiotix Inc
Moderna Inc
MVRIX Corp
Mynvax Pvt Ltd
New Amsterdam Sciences Inc
NextCell Pharma AB
Novavax Inc
Novo Medi Sciences Pvt Ltd
NuGenerex Immuno-Oncology Inc
Nykode Therapeutics ASA
Okayama University
Ology Bioservices Inc
Orlance Inc
Osivax SAS
Park of Active Molecules
Pentavalent Bio Sciences Pvt Ltd
PeptiDream Inc
Pfizer Inc
Pneumagen Ltd
PrEP Biopharm Ltd
Recce Pharmaceuticals Ltd
Red Queen Therapeutics Inc
RedHill Biopharma Ltd
Replikins Ltd
RMIT University
Romark Laboratories LC
SAB Biotherapeutics Inc
Saint Petersburg State University
Sanofi
Scientific Research Institute for Biological Safety Problems
Seqirus Ltd
Serum Institute of India Pvt Ltd
Shandong Luning Pharmaceutical Co Ltd
Shanghai Institute of Biological Products Co Ltd
Shionogi & Co Ltd
Softox Solutions AS
Spectrum Antimicrobials Inc
SpectrumX Holdings Ltd
Starpharma Holdings Ltd
Statera Biopharma Inc
Symvivo Inc
TaiGen Biotechnology Co Ltd
TechnoVax Inc
Texas Tech University Health Sciences Center
The Chinese University of Hong Kong
The Government Pharmaceutical Organization
The Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
The Institute of Vaccines and Medical Biologicals
The National Institute of Allergy and Infectious Diseases
The University of Texas at Austin
Therapeutic Systems Research Laboratories Inc
Tiba Biotech LLC
TrippBio Inc
U.S. National Institutes of Health
University of Arizona
University of Barcelona
University of California Los Angeles
University of Edinburgh
University of Hong Kong
University of Nebraska–Lincoln
University of North Carolina at Chapel Hill
University of Oslo
University of Pittsburgh
University of St. Andrews
University of Wisconsin Madison
Vacthera BioTech GmbH
Vanderbilt University
Vaxart Inc
Vaxess Technologies Inc
Vaxxas Pty Ltd
Veru Inc
Via Nova Therapeutics Inc
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viriom Inc
Vironova Medical AB
Vivaldi Biosciences Inc
Wake Forest University
Walvax Biotechnology Co Ltd
Wuhan Institute of Biological Products Co Ltd
Zhengzhou University
Zosano Pharma Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Influenzavirus A Infections reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Influenzavirus A Infections – Drugs In Development, 2024 in real time.

  • Access a live Influenzavirus A Infections – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more